Sequential use of GM-CSF and IL-2 after chemotherapy could enhance the antigen-presenting function of dendritic cells, promote stronger and more effective immunological activity of antigen-specific CTL, and improve the positive development of tumor immunity and the reconstruction of immune function. This evidence concerns the gene IL2 and neoplasm.